Copyright
©The Author(s) 2021.
World J Gastroenterol. May 7, 2021; 27(17): 2039-2053
Published online May 7, 2021. doi: 10.3748/wjg.v27.i17.2039
Published online May 7, 2021. doi: 10.3748/wjg.v27.i17.2039
VAS item | Normal phosphate group, baseline, mean ± SD | Hypophosphatemia group, baseline, mean ± SD | Difference1 at baseline, mean (95%CI) | P value | Normal phosphate group, change at week 2, mean ± SD | Hypophosphatemia group, change at week 2, mean ± SD | Difference1 at week 2, mean (95%CI) | P value | Normal phosphate group, change at week 6, mean ± SD | Hypophosphatemia group, change at week 6, mean ± SD | Difference1 at week 6, mean (95%CI) | P value |
General weakness | 43.54 ± 28.7 | 31.17 ± 30.5 | 12.4 (-7.6 to 32.4) | 0.205 | -4.98 ± 14.9 | -1.50 ± 17.2 | -3.5 (-14.7 to 7.7) | 0.515 | -10.64 ± 21.9) | -6.33 ± 25.7 | -4.3 (-21.1 to 12.5) | 0.589 |
Fatigue | 37.53 ± 30.0 | 29.58 ± 30.1 | 7.9 (-11.8 to 27.7) | 0.403 | -3.31 ± 19.4 | -1.33 ± 17.9 | -2.0 (-13.9 to 9.9) | 0.728 | -8.93 ± 22.0 | -5.17 ± 26.7 | -3.8 (-21.2 to 13.6) | 0.648 |
Joint pain | 17.30 ± 23.3 | 8.25 ± 14.8 | 9.1 (-1.2 to 19.3) | 0.081 | 0.32 ± 14.3 | -3.09 ± 6.9 | 3.4 (-1.9 to 8.7) | 0.197 | 2.17 ± 18.0 | 0.17 ± 7.4 | 2.0 (-3.8 to 7.8) | 0..489 |
Joint stiffness | 13.31 ± 22.3 | 1.42 ± 3.4 | 11.9 (6.9 to 16.8) | < 0.001 | -0.57 ± 18.1 | -0.64 (2.1) | 0.1 (-3.9 to 4.0) | 0.972 | 0.99 ± 17.7 | 1.75 ± 8.5 | -0.8 (-7.1 to 5.6) | 0.807 |
Muscle pain | 15.35 ± 23.1 | 5.83 ± 14.5 | 9.5 (-0.5 to 19.6) | 0.062 | -1.71 ± 14.6 | 2.45 (8.9) | -4.2 (-10.7 to 2.3) | 0.194 | -0.50 ± 20.6 | -0.17 ± 11.0 | -0.3 (-8.3 to 7.6) | 0.932 |
Bone and skeletal pain | 7.24 ± 19.4 | 1.92 ± 6.6 | 5.3 (-0.3 to 10.9) | 0.061 | 1.85 ± 20.2 | 2.64 (8.7) | -0.8 (-7.7 to 6.1) | 0.817 | 3.42 ± 18.7 | -1.67 ± 6.8 | 5.1 (-0.5 to 10.7) | 0.076 |
Difficulties performing daily activities | 34.38 ± 28.5 | 29.67 ± 29.7 | 4.7 (-14.8 to 24.2) | 0.611 | -3.80 ± 14.9 | -2.17 (23.5) | -1.6 (-16.8 to 13.5) | 0.819 | -9.45 ± 20.0 | -11.00 ± 24.8 | 1.6 (-14.6 to 17.7) | 0.839 |
- Citation: Detlie TE, Lindstrøm JC, Jahnsen ME, Finnes E, Zoller H, Moum B, Jahnsen J. Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact. World J Gastroenterol 2021; 27(17): 2039-2053
- URL: https://www.wjgnet.com/1007-9327/full/v27/i17/2039.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i17.2039